You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 294 No. 5, August 3, 2005 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Correction
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (1)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Oncology
 •Breast Cancer
 •Women's Health
 •Women's Health, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

BRCA Mutations and Ductal Carcinoma In Situ

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The study of the prevalence of BRCA mutations in women diagnosed with ductal carcinoma in situ (DCIS) by Dr Claus and colleagues1 found that 3 (0.8%) and 9 (2.4%) of 369 women with pure DCIS had germ-line BRCA1 or BRCA2 mutations, respectively. Of particular note was 1 woman who at age 37 years was diagnosed with DCIS with comedo necrosis. She had a strong maternal family history of breast and ovarian cancer. This woman carried 2 mutations, 1 each in BRCA1 and BRCA2. The BRCA1 mutation, referred to in this article as W321X, results from a G to A change at nucleotide 1081. The other mutation identified was BRCA2:3398delAAAAG. Both of these mutations are predicted to result in premature termination of the encoded proteins and have been reported in the Breast Cancer Information Core database.2

Claus et al note that this is one of the . . . [Full Text of this Article]

William D. Foulkes, MB, PhD
william.foulkes@mcgill.ca
Program in Cancer Genetics

Nancy Hamel, MSc
Research Institute of the McGill University Health Centre

Kathleen Klein Oros, BSc
Department of Human Genetics
McGill University
Montreal, Quebec



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

BRCA Mutations and Ductal Carcinoma In Situ—Reply
Elizabeth B. Claus, Stacey Petruzella, Ellen Matloff, and Daryl Carter
JAMA. 2005;294(5):554.
EXTRACT | FULL TEXT  

Prevalence of BRCA1 and BRCA2 Mutations in Women Diagnosed With Ductal Carcinoma In Situ
Elizabeth B. Claus, Stacey Petruzella, Ellen Matloff, and Darryl Carter
JAMA. 2005;293(8):964-969.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.